First Berlin Equity Research GmbH’s Post

Missed the event? You can now view the recording and slides using the link below: https://lnkd.in/enmutFXF #Quantum #Europe #GrantFunding #InnovateUK #Innovation #EuropeanQuantum

Biotech Equity Research: Tracking The Promise (And Risk) Of Early Stage Companies Navigating The Public Markets October 3, 2024, 3:00 – 4:00 p.m. EST Speaker: Benjamin J. Burnett, PhD, Managing Director, Equity Research, Stifel Investment Services Ben Burnett, Biotech Equity Research Analyst at Stifel will discuss the intersection of early stage life science companies and finance. We plan to cover recent capital market trends and forecasts, timing the market, and what it takes to become (and be) a public company. Balancing innovation with capital needs requires a good understanding of how and when to access capital, and whether or not this is more easily done as a private or public company. We plan to delve into these concepts in detail and walk through informative case studies of both success and failure.  Zoom Registration: https://lnkd.in/e-hHmpN7

Looking forward to conversations around therapies and technology progressing with improved investor sentiment, albeit with caution! Investing? How commercially viable is the science? What are the product development/CMC and regulatory/clinical risks? What is the competitive landscape? Fundraising? Does your pitch deck and data room position your company to be as investable as possible? Promising non-clinical data? How to turn that into a commercial product? What is the best product development and regulatory strategy? Growing pains? Addressing the various resource gaps in regulatory affairs, regulatory operations, clinical operations, clinical and medical affairs, regulatory and medical writing and many more as you transition the product from one phase to another! Let’s connect and discuss how Boyds can help! #REAIBoston2024 #BiotechweekBoston

The spotlight on early-stage life sciences companies continues to intensify, fueled by heightened investor interest and a surge in M&A activity within the space. In "The Relationship between Funding and Exit Paths," MABA Founder Yaniv Sneor sits down with TEN Capital Network to delve into the intricate dynamics shaping the journey of young life science ventures. With a focus on potential exit strategies, Yaniv provides invaluable insights into how these decisions not only guide the path forward but significantly influence funding considerations. https://lnkd.in/e54xpNPD #LifeSciences #AngelInvesting #MABA 

Epoch 10: Beyond the Bucks - How Specialist Investors Fuel Biotech Success Does the quality of investors on the cap table influence the long term success of the company? 👉 Investor quality drives market cap? 👉 Investor quality can revive neg EV biotechs? 👉 M&A likelihood correlated to investor quality? 👉 M&A returns correlated to investor quality? https://lnkd.in/dEkBy2bY

Today, we published LVS Advisory's Q3 2024 investor letter, in which we discuss our recent investment performance and an investment in Medpace $MEDP. https://lnkd.in/eYuUvBTG

Drop me a message if you want to grab a coffee and find out more about how can reliable data de-risk strategic decisions for a VC, PE and Hedge funds.

The Department of Industry, Science and Resources (DISR) has released another case study featuring PolyActiva, highlighting what can be achieved with support and investment into venture capital companies throughout the venture capital stages. ▶️ https://lnkd.in/g4kZHGnb PolyActiva is impressively pioneering an ocular implant for sustained drug delivery to the eye, which can deliver medication directly to affected tissue. If successful, this could be ground-breaking for glaucoma patients, many of whom are elderly and suffer sever impacts including blindness when forgetting to take medication or applying incorrect doses of it. PolyActiva’s ocular implant is inserted directly into the eye and the technology enables medication to be released as needed to the targeted area. The support and investment PolyActiva has received from Brandon Capital through the Australian Government's Biomedical Translation Fund, has enabled them to conduct the research and clinical trials to nurture innovation into commercially successful companies.   DISR is a partner of Innovation Bay’s VC community, Aurora, and is committed to fostering venture capital investment in startups. Explore some of the Australian Government’s diverse range of programs, including: 👉 Venture Capital Limited Partnerships https://bit.ly/3wzgo3r 👉 Early-Stage Venture Capital Limited Partnerships https://bit.ly/48vsHLu 👉 Australian Funds of Funds https://bit.ly/4bTK1wH 👉 Biomedical Translation Fund https://bit.ly/3uRZVa4 👉 Pooled Development Funds https://bit.ly/49AkPJR   These programs serve as catalysts for growth, facilitating globally competitive businesses. Noteworthy is the substantial impact of DISR's tax concession programs, attracting both foreign and local capital into the Australian venture capital sector. Since the inception of these initiatives, an impressive $30 billion in capital has been committed, benefiting approximately 2,500 early-stage businesses in scaling their ventures.   For those in the VC realm, we invite you to visit DISR's website to discover how their programs can elevate your investment strategies: https://bit.ly/3OjbMof https://bit.ly/3UlQUAE #DISR #VC #venturecapital #innovationbay #partner #departmentofindustryscienceresources #aurora #casestudy #business.gov.au #departmentofhealthandagedcare

BRAIN Biotech AG attends the Baader Investment Conference from 23-26 September 2024 🗓️ 🔔 📈 On 23. September, BRAIN Biotech AG will be actively participating in the 13th edition of the Baader Investment Conference in Munich. Aryan Moelker, [CEO] and Michael Schneiders, [CFO] will be on site to present BRAIN Biotech AG at 11:40 (Forum 2) and to connect with investors within 1-on-1 meetings. #BRAIN Biotech AG #investorrelations #capitalmarkets #BaaderInvestmentConference #BaaderBank

Last week, I attended #JPM2024 in San Francisco and wanted to share some advice for life science founders looking for #funding.   1) Balance your scientific content to ensure it is neither too dense nor too light but has enough detail to fill in the gaps in your audience's knowledge. 2) For potential investors to get behind your company’s mission and give you funding, your investor pitch needs to emphasize the key differentiators of your indication, science, and how your company, if uniquely positioned, can bridge that gap. 3) It's easy to overlook, but make sure you put your most up-to-date pitch deck on your website. Although it seems obvious, website updates get deprioritized all the time. #biotechinnovation #biotech #investorpitch